
News|Articles|May 1, 2002
Cardiac events: Losartan beats beta blocker in patients with diabetes,HTN, & LVH
Therapy starting with the angiotensin receptor blocker (ARB) losartansignificantly reduced the risk of cardiovascular outcomes and new-onsetdiabetes compared with a beta blocker in older high-risk hypertensive patients,said Björn Dahlöf, MD. The improved outcomes with losartan occurredeven after adjusting for small differences in blood pressure reduction betweenthe two study drugs.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HS patients on biosimilar adalimumab lose response faster than those on the original drug
2
Global MS analysis links disability burden to rising economic strain
3
CMS negotiates a 70% discount for Ozempic and Wegovy
4
Virtual care replaces, not adds, Medicare visits for health systems, analysis shows
5






















































